The objective of this analysis was to determine whether changes in baroreflex sensitivity (BRS) within 35 hypertensive patients (25 M, 10 F, mean age 47 years) treated with ␤-blockade as monotherapy relate to reductions in ambulatory blood pressure (BP) or its variability. BP was recorded intra-arterially directly from the brachial artery before and during submaximal exercise. BRS was determined by the phenylephrine injection technique. MAP and its variability were determined for the awake period of 24-h BP monitoring. Subjects were randomised to one of atenolol, metoprolol, pindolol, or propranolol, and restudied after a mean of 5 months. ␤-blockade increased BRS in 24 patients and decreased BRS in 11. BRS increased from 6.53 ؎ 4.94 to 9.40 ؎ 8.62 ms/mm Hg (mean ؎ s.d.) (P Ͻ 0.01). Waking ambulatory MAP decreased from 125.8 ؎ 15.8 to 106.4 ؎ 16.2 mm Hg (P Ͻ 0.0001), but its variability did not change. Higher BRS after chronic ␤-blockade was associated with a decrease in waking ambulatory MAP (r ‫؍‬ ؊0.55,
Introduction
There is considerable variation between hypertensive patients in the blood pressure (BP) response to ␤-adrenoceptor blockade. Hypertensive patients also vary with respect to the effect of chronic ␤-adrenoceptor blockade on baroreflex sensitivity (BRS) for heart rate. [1] [2] [3] [4] [5] [6] The purpose of the present analysis was to determine if these two observations are related.
We have previously reported that the arterial baroreflex regulation of heart rate is impaired in patients with essential hypertension, 7 and that this diminished arterial baroreceptor reflex is associated with increased variability of ambulatory BP and augmented BP responses to mental and physical activities. 8 After chronic ␤-blockade using both cardioselective and non-selective drugs, mean arterial ambulatory BP was significantly decreased, 9 the mean baroreflex sensitivity was significantly increased, 1 and the pressor response to exercise was attenuated. 9 However, there was considerable difference between individuals in the effect of chronic ␤-blockade on BP and on baroreflex sensitivity, increasing in some, and decreasing in others. Moreover, the functional implications of these changes in individual subjects, with respect to ambulatory BP and its variability, have not been reported.
In a recent publication, Vesalainen et al 2 contrasted the effects of 4 weeks of monotherapy with metoprolol and ramipril on heart rate variability, baroreflex sensitivity, and ambulatory BP. Both drugs caused comparable reductions in ambulatory BP, but only metoprolol increased baroreflex sensitivity, and cardiac vagal activity, as assessed by heart rate, heart rate variability, and the high frequency component of heart rate variability during supine rest. Reductions in ambulatory BP correlated significantly with increases in RR interval, its total variability, and high frequency variability. However, there was no significant relationship between changes in baroreflex sensitivity and ambulatory BP in these patients.
We undertook the present re-analysis of our original data set to determine whether improvement in arterial baroreflex sensitivity for heart rate, with chronic ␤-adrenoceptor blockade, will result in correspondingly lower ambulatory BP, or BP varia-bility, or attenuated BP responses to submaximal exercise in hypertensive patients. Because it is now recognised that 24-h ambulatory BP and BP variability are more closely related to end-organ damage in hypertension than is the office BP measurement, [10] [11] [12] and that increased BP variability is an independent adverse risk factor for greater vascular and target organ damage, 10, 13 this question now has clinical relevance.
Subjects and methods
Details of the study protocol have been published. 1, [7] [8] [9] Observations in 35 subjects (25 males, 10 females) referred for the assessment of newly diagnosed, untreated hypertension are reported. Subjects ranged from 16 to 69 years old, with a mean age of 47 (s.d. 12) years. Blood pressure was measured on three or more clinic visits using a standard mercury sphygmomanometer. For the purpose of this study, patients were considered hypertensive when their clinic BP was 140/90 mm Hg or greater, if less than 40 years old, or at or above 160/95 mm Hg, if 40 years or older. Subjects with secondary hypertension were excluded. The study protocol was approved by the Hospital Ethics Committee and informed, written consent was obtained from each subject.
Protocol
Subjects were studied in the morning after a light breakfast at home, avoiding tea, coffee, or cigarettes. Arterial BP was recorded from a left brachial artery cannula, and an adjacent antecubital vein was also cannulated for injection of phenylephrine. ECG (lead II) and intra-arterial BP were recorded continuously for 24 h 7, 8 and digitised for computer analysis. Baroreflex sensitivity was measured during supine rest, using the phenylephrine method. 7, 8 Subjects performed a submaximal bicycle exercise test, 8, 9 then left hospital to resume routine activities, and kept a diary noting, in particular, times of sleep and waking. Because the frequency response of the entire ambulatory recording and replay system falls off rapidly above 10 Hz, 14 we used mean, rather than systolic, BP in these calculations. Average awake mean arterial pressure (MAP) was computed using all valid beats over this period. Blood pressure variability was defined as the standard deviation of the waking mean arterial pressures. 7, 8 After the first study, subjects were randomised to one of four ␤-adrenergic receptor blocking drugs: atenolol (n=9), metoprolol (n = 9), pindolol (n = 9), or slow-release propranolol (n=8). All drugs were taken once daily, in the morning, for 3 to 8 months (mean: 5 months). 1, 9 Subjects were evaluated at monthly intervals at the same time of the day, and the medication dose adjusted if a cuff BP of 140/90 mm Hg or less was not achieved. The study protocol was replicated while on chronic treatment, with the last tablet taken at 08.00 am on the morning of the second study.
Statistics
Data are presented as mean ± standard deviation. Values for baroreflex sensitivity were logarithmically transformed to approximate a normal distribution. Student's t-test was used for paired data when comparing control versus treatment days. P values Ͻ0.05 were considered statistically significant.
Results
Chronic ␤-adrenoceptor blockade increased baroreflex sensitivity in 24 subjects, and decreased it in 11. Patients whose BRS increased tended to be younger (45.6 ± 12.4 vs 50.6 ± 10.9 years), and comprised eight of the 10 women, but these age and sex distributions were not significantly different between the two groups. The average ambulatory mean arterial pressures (126 mm Hg) and heart rates (89 bpm) were identical in the two groups, and the number of patients in whom BRS increased was similar for each drug. Mean values were significantly augmented, from 6.53 ± 4.94 msec/mm Hg before, to 9.40 ± 8.62 msec/mm Hg during ␤-adrenoceptor blockade (P Ͻ 0.01). Corresponding values for the Log transformation of baroreflex sensitivity were 0.725 ± 0.276 and 0.831 ± 0.347 respectively (P Ͻ 0.02).
Paired data were available for analysis of ambulatory BP in 34 patients. As demonstrated in Table 1 , ␤-adrenoceptor blockade reduced significantly MAP, from 125.8 ± 15.8 to 106.4 ± 16.2 mm Hg (P Ͻ 0.0001). ␤-blockade had no effect on the variability of MAP (14.8 ± 4.1 mm Hg untreated vs 15.0 ± 3.2 mm Hg on treatment). The coefficient of variation increased, from 11.9 ± 2.9% to 14.3 ± 3.2% (P Ͻ 0.002).
Increases in Log (BRS) were inversely related to reductions in ambulatory mean arterial pressure (r = −0.55, P Ͻ 0.001) ( Figure 1 ). As illustrated in Figure 2 , there was no relationship between these changes in Log BRS and changes in the variability of mean arterial pressure, as a result of treatment (r = −0.08).
Paired data were available for analysis of BP during exercise in 33 patients. Chronic ␤-adrenoceptor blockade attenuated significantly the increase in BP during bicycle exercise. Systolic BP increased by 59.6 ± 18.5 mm Hg before, and 42.5 ± 20.2 mm Hg after, ␤-blockade (P Ͻ 0.05), while diastolic BP rose by 17.7 ± 9.4 mm Hg before and by 14.7 ± 9.1 mm Hg after ␤-blockade (P Ͻ 0.05). There was a positive linear relationship between increases in Log (BRS) on chronic ␤-adrenoceptor blockade and changes in the systolic BP response to bicycle exercise (Figure 3 , r = 0.63, P Ͻ 0.001).
Discussion
The purpose of this re-analysis was to determine if increases in arterial baroreflex sensitivity for heart rate with chronic ␤-blockade relate to reductions in ambulatory BP, BP variability, or blunted BP responses to bicycle exercise. There are several Mean ± s.d. MAP; mean arterial blood pressure, CV; coefficient of variance, BRS; baroreflex sensitivity. + P Ͻ 0.02, *P Ͻ 0.01, **P Ͻ 0.002, ***P Ͻ 0.0001.
Figure 1
Relationship between changes in arterial baroreflex sensitivity for heart rate (Log (BRS)) and changes in ambulatory awake mean arterial blood pressure after chronic ␤-adrenoceptor blockade (n = 34, r = −0.55, P Ͻ 0.001).
unique aspects to this analysis that distinguish these findings from other reports. Blood pressure was measured directly, using intra-arterial ambulatory monitoring, and baroreflex sensitivity measured directly, using the phenylephrine technique. Only those BP data obtained when subjects were awake and active were included. Patients were studied after long-term treatment (on average 5 months) and, as the recordings were done approximately 5 h after taking the last dose of the drug, the effects of chronic, rather than the acute-on-chronic effect, of ␤-blockade were assessed.
Increased baroreflex sensitivity for heart rate following chronic ␤-blockade in the present study was associated with reduced ambulatory BP. This finding contrasts with the smaller series of Vesalainen et al, 2 who restricted their study to metoprolol. Those authors demonstrated an inverse relationship between changes in ambulatory BP, and indices of cardiac vagal activity based on heart rate variability, but did not detect an inverse relationship between changes in baroreflex sensitivity and ambulatory BP. Despite the fall in average ambulatory BP, increased baroreflex sensitivity was not accompanied by attenuation of blood pressure variability, or by a blunting of the pressor response to exercise.
Our principal observation cannot be explained as a non-specific response to reductions in BP with treatment. In a few of our patients (Figure 1 ), a reduction in awake ambulatory BP was observed in conjunction with a decrease in baroreflex sensitivity. Diuretics, angiotensin-converting enzyme inhibitors and calcium channel antagonists lower BP equally well, but they do not appear to increase baroreflex sensitivity consistently.
2,15-22
For example, in previous reports, captopril increased Figure 2 Absence of relationship between changes in arterial baroreflex sensitivity for heart rate (Log (BRS)) and changes in the variability of ambulatory awake arterial blood pressure (n = 34, r = −0.08, P Ͼ 0.6).
Figure 3
Relationship between changes in arterial baroreflex sensitivity for heart rate (Log (BRS)) and the effect of chronic ␤-adrenoceptor blockade on the rise in systolic blood pressure during bicycle exercise (n = 33, r = +0.63, P Ͻ 0.001).
baroreflex sensitivity in normotensive and hypertensive humans, 15, 16 and lisinopril in elderly hypertensives, 17 whereas ramipril, in a dose therapeutically equal to metoprolol, had no such effect. 2 There are conflicting reports on the effects of calcium channel antagonists on baroreflex sensitivity. [17] [18] [19] [20] In contrast to the present analysis, neither of those studies, nor other studies of short-term treatment with ␤-adrenoceptor antagonists 3, 4 addressed the functional implications of these observations with respect to changes in ambulatory BP or its variability within individual subjects.
When we first reported group mean data from this cohort, 1, 7 we attempted to relate changes in baroreflex sensitivity to changes in systolic BP at the time of the phenylephrine injection, 1 but we did not specifically address the question as to whether changes in baroreflex sensitivity within subjects might determine the ambulatory BP response to ␤-blockade. However, recent developments prompted the analysis of these data, in the present form, with the goal of stimulating hypotheses for testing in future studies. For example, there has been increasing recognition of the importance of ambulatory BP monitoring and BP variability, as risk factors for end-organ damage in hypertension, [10] [11] [12] and increased BP variability is now recognised as an independent adverse risk factor for greater vascular and target organ damage. [10] [11] [12] Reduced baroreflex sensitivity following myocardial infarction is now known to be an important risk factor for premature mortality. 23 Whether increasing baroreflex sensitivity pharmacologically will improve prognosis has not been determined, but the benefits of chronic ␤-adrenoceptor blockade, when given following myocardial infarction, have been well established 24 and there is increasing interest in the administration of ␤-adrenoceptor blockade to patients with left ventricular dysfunction. 25 There is considerable variation between patients in the BP response to ␤-blockade, and the mechanism by which ␤-adrenoceptor antagonism reduces BP remains obscure. Our data, which are derived from the entire ambulatory recording during the awake period, argue for a potential relationship between this hypotensive action, and augmented baroreflex sensitivity for heart rate. If so, this may be mediated at the level of the arterial baroreceptor afferents. 26 Long-term ␤-adrenoceptor blockade also reduces central sympathetic outflow. 27 Thus, there may be two mechanisms by which the ␤-adrenoceptor blockade could cause the vagal control of heart rate to predominate: a reduction in sympathetic traffic to cardiac nerves, and reduction in the normal sympathetic antagonism of vagal effects at the sinoatrial node. 28 If the BP response to ␤-adrenoceptor blockade is indeed a function of changes in baroreflex sensitivity, future studies might focus on the reasons for the variability between subjects of the effects of ␤-blockade on the baroreflex control of heart rate. One factor may be the duration of hypertension that has elapsed prior to the initiation of treatment. When given to rats early in the course of spontaneous hypertension, atenolol increased the gain of the baroreceptor reflex control of renal sympathetic nerve activity, and of heart rate, whereas, when given late in the course of spontaneous hypertension, these effects of atenolol were lost. 29 The authors of this experimental study suggested that there may be a critical phase representing the optimal time to initiate antihypertensive treatment. 29 A second factor may be patient age. It has been proposed that increases in BRS with chronic ␤-adrenoceptor blockade occur primarily in younger hypertensives, 5, 6 possibly due to alterations in compliance of the arterial conduits that house arterial baroreceptor afferents, or due to an age-related decrease in cardiac muscarinic receptor responsiveness. 30 Subjects whose BRS decreased tended to be older, in the present study, but this difference was not significant.
We did not address the issue of how these changes in baroreflex sensitivity relate to changes in central and peripheral haemodynamics at rest, and during bicycle exercise, or the influence of these drugs on sympathetic nerve traffic to the heart and periphery. In the absence of such information, we can only speculate as to why there was a direct relationship between changes in baroreflex sensitivity and changes in systolic BP during bicycle exercise. For example, pulse pressure may have increased to compensate for a blunted heart rate response to exercise.
These novel observations suggest that the antihypertensive action of ␤-blockade may be a function of the effect of this class of drugs on the arterial baroreflex sensitivity for heart rate. However, our observations would indicate that ␤-adrenoceptor antagonists are unlikely to attenuate any vascular and target organ damage in hypertensive patients arising from their increased BP variability. An effect of ␤-adrenoceptor blockade on baroreflex sensitivity may be fundamental to the cardioprotective action of this class of drugs following myocardial infarction, or in mediating the medium-to long-term benefits of ␤-blockade in heart failure. If so, those patients whose baroreflex sensitivity does not improve following chronic ␤-adrenoceptor blockade may be at highest risk for adverse outcome in these two conditions. This hypothesis merits prospective evaluation.
